ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2026
Sex disparities in melanoma stage, recurrence and mortality: A Danish cohort study, 2004 to 2024.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sex disparities in melanoma stage, recurrence and mortality: A Danish cohort study, 2004 to 2024.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Sex disparities in melanoma: Beyond stage at diagnosis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Clinical and Dermoscopic Determinants of Surgical Decision-Making in Skin Cancer Screening: A Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMale sex appears to be associated with more advanced melanoma stage and inferior prognosis, but population-based data on sex disparities in stage-specific recurrence and mortality remain limited.
objectivesThe objective of this study was to examine sex disparities in (1) melanoma stage at diagnosis and (2) stage-specific recurrence and long-term melanoma-specific mortality.
methodsThis population-based cohort study included all Danes with melanoma from 2004 to 2022 identified in the Danish Cancer Register. The impact of sex on melanoma stage diagnosis (Breslow thickness, presence of ulceration, presence of lymph node metastases and presence of distant metastases) was investigated using multivariable logistic regression models. Furthermore, we examined melanoma recurrence, melanoma-specific and overall mortality for stage I + II (localized), stage III (locoregional) and stage IV (metastatic) melanoma in a competing risk model, adjusting for stage at diagnosis, comorbidity, age and calendar year.
resultsThis study included 30,497 individuals diagnosed with melanoma; the median follow-up time was 8 years, and 14,409 (47%) were male. Males had, compared to females, an increased adjusted odds ratio (aOR) of Breslow thickness >4 mm (aOR 1.45, 95% CI: 1.31-1.59), presence of ulceration (aOR 1.28, 1.18-1.39), >1 lymph node metastases (aOR: 1.58, 1.38-1.80) and distant metastases (aOR: 1.69, 1.48-1.94). In stage-adjusted analyses, males with localized melanoma had an increased adjusted hazard ratio (aHR) of melanoma recurrence (aHR: 1.38, 1.27-1.51) and melanoma-specific mortality (aHR: 1.51, 1.34-1.71). In patients with locoregional and metastatic melanoma, males had an inferior prognosis, but it was less pronounced.
conclusionsThis nationwide cohort study found that males were more likely to be diagnosed with more advanced stages of melanoma. Analyses stratified by stage at diagnosis, showed that males had a 20%-50% higher risk of melanoma recurrence, melanoma-specific and overall mortality across localized, locoregional and metastatic melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.